Identification of molecularly targeted therapy-induced immunopeptidome in diffuse midline glioma (DMG).

ABSTRACT:

Introduction

Diffuse midline glioma (DMG) with the H3K27M mutation remains one of the most treatment-resistant pediatric brain tumors, in part due to limited antigen presentation and immune visibility. Exploring how glioma biology and therapeutic interventions influence immune recognition offers new opportunities to identify tumor-specific immune targets.

Materials and methods

We performed immunopeptidomics on human cell line derived tumor tissue for DMG and glioblastoma (GBM) and defined how MTX-241F, a selective EGFR/PI3K inhibitor, changes the tumor immunopeptidome. Immunopeptides were isolated from xenografted tumors by capturing MHC-I bound peptides followed by mass spectrometry. Comparative analyses were performed across tumor type (DMG vs. GBM) and treatment condition

SUBMITTER: Khairkhah N 

PROVIDER: S-EPMC12918168 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature